After showing promising result in preclinical models (TNBS colitis in rats and adoptive transfer colitis in Scid mice) (139) and after successfully completing a phase II study in moderate-to-severe UC (140), first results from phase III trials of the oral S1PR1- and S1PR5-selective agonist ozanimod for the treatment of moderate-to-severe UC were presented recently. Here, S1PR5 is linked to colitis.